Alzheimer’s disease
Top Ten most popular articles on Pharmafile.com this week
February 16, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's disease, Roche, Top 10 news, Top ten news, Trump, biotech, drugs, pharma, pharmaceutical
Another week is finished and it’s been a disastrous one for research into a potential treatment for Alzheimer’s disease. Two of …
Diabetes drugs show potential in treating Alzheimer’s
January 3, 2018Research and Development Alzheimer's disease, biotech, drugs, pharma, pharmaceutical
A group of researchers at Lancaster University have identified a drug currently used to treat type 2 diabetes that has …
Blood test developed for early Alzheimer’s detection
July 20, 2017Medical Communications, Research and Development Alzheimer's disease, biotech, drugs, pharma, pharmaceutical
A blood test has been created that could offer an inexpensive, and less invasive, alternative to current Alzheimer’s disease tests. …
Atomic structure of tau revealed opening up new Alzheimer’s targets
July 6, 2017Research and Development Alzheimer's disease, dementia, tau protein, tau tangle
It is a research breakthrough that has been touted as the biggest development in Alzheimer’s disease research for a quarter …
Lilly forced to abandon Alzheimer’s drug after failed trial
November 24, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Alzheimer's disease, Eli Lilly
Eli Lilly announced that the results of its ‘Expedition 3’ trial for an experimental Alzheimer’s disease drug meant that they would …
FDA fast tracks Alzheimer’s drug from Lilly, AstraZeneca
August 22, 2016Manufacturing and Production, Research and Development Alzheimer's disease, AstraZeneca, BACE, lilly, phase III
AstraZeneca and Eli Lilly have announced that the US Food and Drug Administration (FDA) has granted AZD3293 its fast track …
Lundbeck, Otsuka’s trial Alzheimer’s disease drug gets US FDA fast track designation
July 8, 2016Medical Communications, Research and Development Alzheimer's disease, Lundbeck, Otsuka, US FDA, drug development, drug trial, fast track designation
H. Lundbeck A/S (CPH: LUN) and Otsuka Pharmaceutical said the US Food and Drug Administration (FDA) have granted Fast Track …
Lilly changes Alzheimer’s trial endpoint – shares fall
March 16, 2016Research and Development Alzheimer's disease, Eli Lilly, solanezumab
Shares in Eli Lilly fell more than 4% yesterday when it announced it was changing the primary endpoint of a closely-watched …
Alzheimer’s disease market set to double to $10.4 Billion by 2021
February 11, 2016Research and Development, Sales and Marketing Alzheimer's disease
The Alzheimer’s disease market will more than double from just under $5 billion in 2014 to an estimated $10.4 billion …
Lilly and Roche team up on new Alzheimer’s diagnostic test
January 28, 2016Research and Development Alzheimer's disease, Diagnostics, Roche, dementia, lilly
Eli Lilly has partnered with Roche Diagnostics to advance its development of a cerebrospinal fluid test for amyloid-beta 1-42, which …
Alzheimer’s drugs prescriptions rise six-fold in a decade
January 19, 2016Manufacturing and Production Alzheimer's, Alzheimer's disease, NHSIC, dementia, prescribing
The number of prescriptions dispensed in England for approved medicines to treat Alzheimer’s increased from 502,000 in 2004 to 3 …
The case for adaptive trials in dementia
January 6, 2016Manufacturing and Production, Research and Development Alzheimer's, Alzheimer's disease, adaptive trials, research
An ageing population and widespread chronic neuro-degenerative disease will make dementia an ever increasing burden on society, families and the …
Neurimmune kicks off late-stage Alzheimer’s study
September 9, 2015Research and Development Alzheimer's disease, Biogen, Neurimmune, aducanumab, neurology
Neurimmune and its development partner Biogen are beginning a Phase III study of the companies’ potential Alzheimer’s treatment aducanumab. The …
Neurology comes to the fore
September 7, 2015Manufacturing and Production, Research and Development, Sales and Marketing Alzheimer's disease, multiple sclerosis, neurology
Neurology is an area where pharma has struggled to deliver in recent years.Yet the high unmet need for drugs to …
Amgen and Novartis partner on Alzheimer’s and migraine treatments
September 2, 2015Research and Development Alzheimer's disease, Amgen, Novartis, migraine, neurology, neuroscience
Amgen and Novartis have announced a global collaboration to develop neuroscience treatments in Alzheimer’s disease and migraine. The companies plan …
Latest content
Five Facts about cardiovascular disease
